Use of cross species genomic profiling identifies pathways and genes differentially regulated in prostate cancer cells treated with Soy Protein Isolates or purified Genestein.

2230

Soy protein intake is associated with a decreased incidence of prostate cancer in humans, and Soy Protein Isolates have been shown to decrease the incidence of prostate cancer in rat prostate cancer model systems. The main purified compound from Soy Protein Isolates has been Genestein, but this purified phytoestrogen fails to recapitulate all the features of the Soy based diet. In order to better understand the effects of Soy Protein Isolates we have treated rat and human prostate cancer cell lines with either Soy Protein Isolates or purified Genestein. The observed decreased in vitro cell growth was then correlated with the associated genomic expression profiles using rat or human spotted cDNA arrays. The data was bioinformatically analyzed within and across species to identify common changes in expression profiles associated with the Soy Protein or Genestein treatments. Data mining and metabolic/biologic pathway analysis identified differential regulation of the cellular senescence, thyroid hormone response, intracellular transport, and frizzled-beta catenin-wnt pathways along with identification of genes differentially regulated between Soy Protein Isolates and Genestein including PPAR-gamma, xenobiotic drug transporter (breast cancer resistance protein), RXR-alpha and RXR-beta. Further evaluation and discussion of these genes and pathways will be described.